Aridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25
December 28, 2022 08:30 ET
|
Aridis Pharmaceuticals, Inc.
Los Gatos, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective...
(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
December 12, 2022 08:05 ET
|
Aridis Pharmaceuticals, Inc.
Los Gatos, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company today announced the Cystic Fibrosis Foundation invested $4.85 million in...
Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
December 12, 2022 07:00 ET
|
Aridis Pharmaceuticals, Inc.
Los Gatos, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company today announced the Cystic Fibrosis Foundation invested $4.85 million in...
Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical
December 05, 2022 07:00 ET
|
Aridis Pharmaceuticals, Inc.
The Sudan Ebola and Marburg mAb programs were awarded approximately $190 million of BARDA funding covering manufacturing, efficacy and safety evaluations, and regulatory approval Los Gatos, Calif.,...
Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients
November 30, 2022 07:00 ET
|
Aridis Pharmaceuticals, Inc.
Los Gatos, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective...
Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases
November 22, 2022 09:10 ET
|
Aridis Pharmaceuticals, Inc.
The Company’s superiority Phase 3 ‘ASAP-1' study of AR-301 monoclonal antibody in S. aureus pneumonia and the pending data readout will be a focus of the KOL event Los Gatos, Calif., Nov. 22, 2022 ...
Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update
November 21, 2022 18:30 ET
|
Aridis Pharmaceuticals, Inc.
Top-line data from the Phase 3 clinical trial evaluating AR-301 for the treatment of VAP expected in December of this year LOS GATOS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aridis...